Characteristics of Immunobiology in the Tumor Microenvironment- Development of ImmunotherapiesView this Special Issue
Research Article | Open Access
FGFRL1 Promotes Ovarian Cancer Progression by Crosstalk with Hedgehog Signaling
Fibroblast growth factor receptor-like-1 (FGFRL1) has been identified as the fifth fibroblast growth factor receptor. So far, little is known about its biological functions, particularly in cancer development. Here, for the first time, we demonstrated the roles of FGFRL1 in ovarian carcinoma (OC). An array and existing databases were used to investigate the expression profile of FGFRL1 and the relationship between FGFRL1 expression and clinicopathological parameters. FGFRL1 was significantly upregulated in OC patients, and high FGFRL1 expression was correlated with poor prognosis. In vitro cell proliferation, apoptosis and migration assays, and in vivo subcutaneous xenograft tumor models were used to determine the role of FGFRL1. Loss of function of FGFRL1 significantly influenced cell proliferation, apoptosis, and migration of OC cells in vitro and tumor growth in vivo. Chromatin immunoprecipitation PCR analysis and microarray hybridization were performed to uncover the mechanism. FGFRL1 expression could be induced by hypoxia through hypoxia-inducible factor 1α, which directly binds to the promoter elements of FGFRL1. FGFRL1 promoted tumor progression by crosstalk with Hedgehog (Hh) signaling. Taken together, FGFRL1 is a potential predictor and plays an important role in tumor growth and Hh signaling which could serve as potential therapeutic targets for the treatment of OC.
Ovarian carcinoma (OC) has the highest mortality rate among the malignancies of the female reproductive tract. In the United States, more than 22,000 women were diagnosed with OC and more than 14,000 women died in 2016 . The poor survival rate is due primarily to the advanced stage of disease and widespread metastases at the time of diagnosis. Therefore, an insight into the understanding of the molecular mechanisms underlying the progression of OC and identifying new targets and strategies is pressing.
Fibroblast growth factor-like-1 (FGFRL1) is a member of the fibroblast growth factor receptor (FGFR) family [2–6]. Fibroblast growth factors (FGF) and their receptors are known for regulating numerous cellular processes. Activated FGFRs have become a promising potential target in many cancers, including ovarian carcinoma. FGFRL1 encoding the protein composed of a cytoplasmic His-rich motif without the intracellular tyrosine kinase domain. Owing to the fact, it was thought to be a decoy receptor and exert no or negative effect on cell proliferation in some studies [7, 8]. However, FGFRL1 is involved in multiple cellular functions. FGFRL1 was reported to take part in the progression of endometriosis  and induce cell-cell fusion in CHO cells . Targeted deletion of FGFRL1 leads to severe kidney dysgenesis . FGFRL1 was identified to enhance ERK1/2 signaling through association of SHP with the receptor’s intracellular SH2-binding motif in beta-cells in the pancreas . In high-grade serous ovarian tumor, FGFRL1 mRNA isoform was identified with tumor-specific expression . FGFRL1 could accelerate tumor growth in different neoplastic diseases [14–16]. However, little is known about cellular functions of FGFRL1 in ovarian carcinoma.
Herein, we analyzed the expression pattern and clinical significance of FGFRL1 in ovarian cancer and tried to detect important pathways as well as key genes in order to understand the mechanism of FGFRL1 contributing to the development of ovarian cancer.
2. Material and Methods
2.1. Case Cohort
Human ovarian cancer tissue microarrays containing 90 cases of ovarian carcinoma and 10 cases of normal ovarian tissues were obtained from Obstetrics and Gynecology Hospital, Fudan University. The study was approved by the Research Ethics Committee of Obstetrics and Gynecology Hospital, Fudan University.
2.2. Cell Culture
Human ovarian cancer cell lines ES2, SKOV3, OVCAR8, Hey, and human immortalized ovarian epithelial cell line Moody were preserved at Shanghai Cancer Institute. All cells were cultured in indicated medium and supplemented with 10% fetal bovine serum (Invitrogen), 100ug/ml streptomycin, and 100 units/ml penicillin at 37°C with 5% CO2. Aiming to hypoxia treatment, OC cells were cultured in the incubator with 1% O2 gas mixture for the desired period of time. Prior to CHIP assay, Cobalt chloride (CoCl2) was used at the final concentration of 100 μM in the OC cell culture media and incubated for 6 hours to induce hypoxia .
The tissue microarray (TMA) slide was prepared for immunohistochemistry (IHC) staining, and the primary antibody FGFRL1 (Rabbit polyclonal antibody, Novus) was used. The FGFRL1 staining intensity was scored as follows: negative, 0; weak, 1; moderate, 2; and strong, 3. Scoring of positive staining cells was conducted from 0–4: 0–5%, 0; 6–35%, 1; 36–70%, 2; and more than 70%, 3. The final score was designated using FGFRL1 staining intensity score × FGFRL1-positive cell score. The final score was determined as follows: a score of 0 or 1 was considered low expression, and a score of 2 or 3 was considered high expression. The results were evaluated by two experienced pathologists in a blinded manner.
2.4. Real-Time PCR
The total RNA was extracted from OC cells using RNAiso Plus (Takara, Tokyo, Japan). The reverse transcription was performed using a Prime-Script RT-PCR Kit (Takara, Tokyo, Japan). The qPCR was performed using ABI 7500 System (Applied Biosystems Inc. USA) with SYBR Green Master Mix (Takara, Japan). The data were analyzed to quantify the relative mRNA expression levels of genes. The primers used in this study are shown in Supplementary Table S2.
2.5. Western Blotting
OC cells were lysed in IP lysis buffer (Beyotime, Jiangsu, China) containing proteinase and phosphatase inhibitors (Selleck, TX, USA). Proteins were separated through SDS-PAGE and incubated overnight at 4°C using primary antibodies as follows: anti-FGFRL1 (Abcam, UK, ab112917, 1 : 100) and HIF1α (Abcam, UK, Ab16066, 1 : 1000). The bands were detected using ECL Western Blotting Detection Reagents (Millipore).
2.6. Short Interfering RNA-Based Gene Knockdown
OC Cells were transiently transfected using the Lipofectamine RNAiMAX reagent (Invitrogen), Opti-MEM reduced-serum medium (Invitrogen), and small interfering RNA (siRNA) oligonucleotides (Supplementary Table S1) for FGFRL1 silencing. After 48 hours, siRNA-treated cells were used in a subsequent experiment.
2.7. Cell Viability Assay
OC cells were transfected with FGFRL1 siRNA. After 48 hours, cell viability was measured using Cell Counting Kit-8 (CCK-8, Dojindo, Japan). The absorbance was detected at 450 nm using a microplate reader. The experiment was performed in triplicate and repeated triple.
2.8. Migration Assay
About 2 × 104 cells in 200 μL medium were seeded into the upper chambers (Corning, NY, USA) with an 8 μm pore in 24-well plates. Medium containing 10% FBS was added to the lower chambers. After 16 hours, the cells which remained on the upper surface of the chambers were removed. The migrated cells were fixed and stained with crystal violet. The cells were counted in five random microscopic fields per well.
2.9. Wound Healing Assay
OC cells were seeded, and the wound was created by scraping with a pipette tip while cells were 90% confluent. After the debris was washed with PBS, photographs were taken to assess the ability of the cells to migrate into the wound area at 0 h and 24 h. Experiments were carried out in triplicate.
2.10. Apoptosis Assay
OC cells were cultured under serum deprivation overnight and detached with 0.25% trypsin without EDTA. Then cells were washed with 1 × PBS, stained with 50 μg/ml propidium iodide and Annexin V-FITC (BD Pharmingen, USA) following the manufacturer’s protocols. The percentage of Annexin V (+) and PI (−) cells was analyzed by flow cytometry.
2.11. Animal Experiments
Short hairpin RNA- (shRNA-) containing plasmids were packaged into lentivirus, and virus titers were determined. The sequence targeting FGFRL1 is as follows: sh: 5-GTCGTGCTGGATGACATTAGC-3. For in vivo tumor formation, 2 × 106 sh-OVCAR8 cells were subcutaneously injected into one flank of each mouse. After 6 weeks, the mice were sacrificed, and the parameters were measured. Mice were manipulated and housed according to protocols approved by the East China Normal University Animal Care Commission.
2.12. Chromatin Immunoprecipitation (CHIP) Assay
CoCl2 was used to induce hypoxia in the hypoxia group. Cells were cross-linked with 1% formaldehyde, terminated by adding glycine (1.25 M), lysed, and fragmented. The extracts were incubated with the anti-HIF1α antibody or control IgG with rotation overnight at 4°C. After IP, the protein DNA cross-links were reversed. PCR was performed with the input DNA and the immunoprecipitates, and the products were separated by agarose gel electrophoresis. The primers used here are listed in Supplementary Table S2.
2.13. Dual-Luciferase Reporter Assay
FGFRL1 promoter-luciferase reporter plasmids were constructed in the pGL4 plasmid. A dual luciferase reporter assay (Promega, WI, USA) was performed following the manufacturer’s instructions.
2.14. Microarray Hybridization
Si-control/ES2, Si-FGFRL1/ES2 cells, Si-control/OVCAR8, and Si-FGFRL1/OVCAR8 cells were homogenized in RNAiso Plus (Takara, Tokyo, Japan). The Affymetrix human genome U133 gene chip sets were performed by Shanghai Biotechnology Corporation. Transcript profiling was submitted to the National Center for Biotechnology Information’s GEO database, and the repository URL and the data accession numbers are GSE 106549.
2.15. Statistical Analysis
The SPSS 19.0 software (IBM Corporation) was used for statistical analyses. The comparisons were taken using two-tailed paired Student’s t-tests. The correlation was performed by a chi-square or Fisher’s exact tests. Graphic representations were tested with GraphPad Prism software (San Diego, CA). For survival analysis, the Kaplan-Meier method was carried out and differences were analyzed by the log-rank test. Values of were considered to be statistically significant.
3.1. The Expression of FGFRL1 Is Upregulated in OC
By browsing databases, we found that FGFRL1 was upregulated in various tumors. We analyzed three independent microarray datasets from GEO datasets for FGFRL1 mRNA expression level. The results showed that FGFRL1 expression was significantly upregulated in serous borderline ovarian tumors (SBOT), low-grade serous ovarian carcinomas (LGSOC), and high-grade serous ovarian carcinomas (HGSOC) in comparison with ovarian surface epithelia (OSE) using GSE27651 (, , , and ; Figure 1(a)) . FGFRL1 expression was also significantly higher in SOC tissues than OSE or normal tissues using GSE18520 (, ; Figure 1(b))  and GSE12470 (, ; Figure 1(c)) . Subsequently, to further address the protein change of FGFRL1 in OC, we performed IHC in a TMA of 90 OC samples and 10 noncancerous samples. The protein level of FGFRL1 was remarkably higher in OC tissues than that in normal tissue by IHC (Figures 1(d) and 1(e)).
3.2. Relationship between FGFRL1 Expression and Clinical Parameters of OC
To evaluate the clinical significance of FGFRL1 expression in OC, we assessed the relationship between FGFRL1 protein expression and clinical parameters (Supplementary Table S3). The results showed that FGFRL1 expression was significantly associated with histological grading.
3.3. High FGFRL1 Expression Predicts Poor Prognosis in OC
The correlation between FGFRL1 expression and clinical follow-up information was analyzed in order to evaluate the prognostic significance of FGFRL1 in OC patients. We evaluated the prognostic value of FGFRL1 at mRNA level using a Kaplan-Meier plotter tool with a total of 1648 cases enrolled from TCGA (the Cancer Genome Atlas) and multiple GEO datasets. As shown in Figure 1(f), patients with higher FGFRL1 level had significantly shorter survival time than those with a lower FGFRL1 level. Furthermore, the relationship between FGFRL1 expression and the overall survival in OC patients with advanced grade (II-III) was evaluated. The overall survival was shorter in advanced patients with high FGFRL1 expression (Figure 1(g)).
3.4. FGFRL1 Gene Is Infrequently Amplified and Could Be Induced by Hypoxia via Hypoxia-Inducible Factor 1α (HIF1α) in OC
In order to identify whether gene amplification contributes to higher FGFRL1 expression in OC, our analysis of cancer genomics in TCGA revealed that gene amplification was infrequent in FGFRL1 gene and only 21 of 301 samples (6.75%; Figure 2(a)). The evidence is insufficient to explain the upregulation of FGFRL1 expression in OC.
Thus, we need more evidence to explain the upregulation of FGFRL1 expression. Hypoxia microenvironments are often found in many solid tumors including prostate cancer, brain tumor, and ovarian carcinomas [21–23]. Hypoxia treatments (2% O2) were performed in OC cells. The existing dataset showed that FGFRL1 expression was significantly induced after hypoxia treatment in SKOV3 cells in the GSE53012 dataset (Figure 2(b)). Our results revealed that the expression of FGFRL1 was induced by hypoxia treatment in OC cells at indicated time intervals (Figures 2(c) and 2(d)).
We tried to identify transcription factor responsible for hypoxia-induced upregulation of FGFRL1 expression. It has been reported that hypoxia-inducible factor 1 (HIF1) is a key molecule to help the hypoxia cells to compensate the hypoxia at the molecular level. Under hypoxic conditions, HIF-1α subunit can be stabilized and accumulated. Our results also suggest that hypoxia can induce the expression of HIF1α in OC cells.
To identify the role of HIF1α, we first examined the FGFRL1 expression level after HIF1α silencing with siRNAs under hypoxia condition for 6 hours. HIF1α knockdown reduced FGFRL1 expression in OC cells (Figures 2(e) and 2(f)). These findings suggest that FGFRL1 is the downstream target of HIF1α in OC cells. We hypothesized that HIF1α directly regulated FGFRL1 by transcription of the FGFRL1 promoter and conducted 10 pairs of primers according to the promoter of FGFRL1 (Figure 2(g)). We mimicked chemical hypoxia condition using CoCl2 in OC cell for 6 hours. CHIP PCR was performed in OC cell and indicated that HIF1α was directly bound to the second and tenth region in the FGFRL1 promoter under the hypoxia condition (Figure 2(h)). Two putative HIF1α-binding sites in the FGFRL1 promoter located at −2649 to −2632 and −27 to −11 were identified (Figure 2(i)). We constructed the wild-type and mutant FGFRL1 promoter luciferase reporters and used them in reporter assays. Reporter assays further confirmed that the transcriptional activity of FGFRL1 was significantly induced by HIF1α under hypoxia condition and was decreased by transduction of a mutant FGFRL1 promoter luciferase reporter (Figures 2(j) and 2(k)). Collectively, our findings supported that HIF1α could transcriptionally activate FGFRL1 by binding to two predicted sites in the FGFRL1 promoter.
3.5. FGFRL1 Affects OC Cell Proliferation, Apoptosis, and Cell Migration In Vitro
Based on FGFRL1 high expression with poor clinical prognosis, we further investigated the biological cellular functions of FGFRL1 in OC cells. Consistent with the findings in OC tissues, FGFRL1 expression was higher in OC cells than in a nonmalignant immortalized ovarian cell line Moody at protein level (Figure 3(a)). The siRNA-mediated loss of function for FGFRL1 resulted in >75% reduction in FGFRL1 expression in OC cells by RT-PCR and Western blot (Figures 3(b) and 3(c)). CCK-8 assay showed that knockdown of FGFRL1 significantly inhibited cell proliferation in OC cells (Figure 3(d)). The effect of FGFRL1 on cell apoptosis was also investigated by flow cytometric analysis. The silencing of FGFRL1 increased the apoptosis rate of OC cells (Figure 3(f)). Consistent with this, caspase-3/7 activity in OC cells was significantly increased by silencing of FGFRL1 (Figure 3(e)). The transwell model and wound healing assays were used to analyze the cell migration of OC cells after knockdown of FGFRL1 (Figures 4(a) and 4(b)).
3.6. FGFRL1 Suppresses Xenograft Tumor Growth In Vivo
FGFRL1 expression was reduced stably using shRNAs. To investigate the effect of FGFRL1 in vivo, OVCAR8 cells were transplanted into nude mice subcutaneously. The weight and size of tumors formed by sh-FGFRL1 cells were significantly decreased in comparison with the tumors formed by the sh-control group (Figure 4(c)). The results showed that FGFRL1 promoted tumor growth in OC.
3.7. FGFRL1 Regulates the Hedgehog (Hh) Signaling Pathway
To elucidate the signaling pathways that were significantly altered following the silencing of FGFRL1 expression, we performed global gene profiling experiments of the OVCAR8 and ES2 cells after knockdown of FGFRL1 using siRNAs. We conducted pathway analysis with the differentially expressed genes in two OC cells. Functional and gene network analysis with differentiated genes revealed significantly altered pathways (Figures 5(a) and 5(b)). Meanwhile, we analyzed a microarray dataset from GSE9891 and divided expression data into two groups named the high expression group () and low expression group () according to the expression level of FGFRL1. Gene set enrichment analysis (GSEA) using hallmark gene sets was performed and showed striking alterations in several pathways including the Hh signaling pathway (Figure 5(c)). The cross of the significantly altered pathways in two OC cells and ovarian tissues showed that the Hh signaling pathway was significantly altered after FGFRL1 knockdown (Figure 5(d)).
To further evaluate whether knockdown of FGFRL1 inhibited downstream Hh signaling, the Gli-luciferase reporter was used in luciferase reporter assays. As expected, luciferase reporter assays further confirmed that the activity of the Hh signaling pathway was significantly inhibited after knockdown of FGFRL1 (Figure 5(e)). Furthermore, the mRNA expression level of target genes (Gli1 and Gli2) of Hh signaling in FGFRL1-reduced OC cells was significantly decreased compared to the control, indicating that FGFRL1 silencing inhibited the downstream of the Hh signaling pathway (Figures 5(f) and 5(g)).
In this study, we observed that FGFRL1 was commonly upregulated in both OC cells and tissues compared with normal controls. High FGFRL1 predicted poor prognosis in OC and other tumors. In OC cells, FGFRL1 expression could be induced by hypoxia via HIF1α. FGFRL1 exhibited oncogenic functions in promoting cell proliferation and cell migration by activating Hh signaling.
FGFRL1 was demonstrated to express preferentially in skeletal tissues, and small amounts of FGFRL1 mRNA were detected in other tissues such as the heart . In the current study, FGFRL1 was highly expressed in OC tissues and other different neoplastic diseases. However, the reason why FGFRL1 is upregulated in OC is still unclear. Although DNA copy number amplification partly contributed to the increased expression of FGFRL1 in OC, we need more evidence to explain the upregulation of FGFRL1. It has been reported that solid tumor frequently encounters hypoxia stress, especially measurable sized solid tumors and the overexpression of HIF1α has been observed in many tumors [24, 25]. In this study, FGFRL1 expression could be induced under hypoxia condition in OC cells, which was consistent with previous study . Our data further demonstrated that HIF1α was essential for the hypoxia-induced FGFRL1 expression by transcriptionally binding to the FGFRL1 promoter based on a series of assays.
To evaluate the prognostic value of FGFRL1 in OC, we performed Kaplan-Meier survival analysis. High FGFRL1 expression was associated with poor prognosis in OC patients. This was consistent with the findings in this study that elevated FGFRL1 was an indicator for the poor prognosis in gastric carcinomas.
It was reported that downregulation of FGFRL1 decreased cell proliferation by promoting the proportion of cells in G1/G0 phase and decreasing in S and G2/M phases in human laryngocarcinoma cancer and esophageal squamous cell carcinoma [14, 16]. Our data revealed that no significant difference was observed in cell cycle assay. Herein, we explored that FGFRL1 promoted cell proliferation, inhibited apoptosis and, promoted cell migration of OC cells. The discrepancy might be due to different mechanisms in specific tumors.
FGFRL1 was ever thought to have no effect on ERK1/2 signaling without the intracellular tyrosine kinase domain . However, FGFRL1 was identified to enhance ERK1/2 signaling through association of SHP with the receptor’s intracellular SH2-binding motif . Our study demonstrated that Hh signaling was activated by FGFRL1.
In conclusion, we describe FGFRL1 as a crucial factor in the clinical outcome and progression during human OC, indicating it is a novel therapeutic target that can be used for the treatment of OC.
Our results demonstrated that FGFRL1 was commonly upregulated in OC cells and tissues compared with normal controls. High FGFRL1 predicted poor prognosis in OCs. FGFRL1 expression could be induced by hypoxia via HIF1α in OC cells. FGFRL1 significantly promoted cell proliferation and migration of OC cells in vitro and tumor growth in vivo. FGFRL1 exhibited oncogenic functions in promoting cell proliferation and cell migration by crosstalk with Hh signaling. Taken together, this study provides valuable insight into FGFRL1, which plays an important role in tumor growth and Hh signaling which could serve as potential therapeutic targets for the treatment of OC.
Conflicts of Interest
The authors declare no conflicts.
Haiyan Tai and Zhiyong Wu share co-first authorship.
This work was supported by funding from National Key R&D Program of China (2016YFC1303100).
Supplementary Table S1: SiRNAs used in this study. Supplementary Table S2: primers used in this study. Supplementary Table S3: correlations between FGFRL1 expression and clinicopathologic features in OC patients. (Supplementary Materials)
- R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA: a Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016.
- B. Trueb, L. Zhuang, S. Taeschler, and M. Wiedemann, “Characterization of FGFRL1, a novel fibroblast growth factor (FGF) receptor preferentially expressed in skeletal tissues,” Journal of Biological Chemistry, vol. 278, no. 36, pp. 33857–33865, 2003.
- S.-O. M. Injune Kim, K.-H. Yu, U.-H. Kim, and G. Y. Koh, “A novel fibroblast growth factor receptor-5 preferentially expressed in the pancreas,” Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, vol. 1518, no. 1-2, pp. 152–156, 2001.
- J. F. Matthew Sleeman, M. McDonald, S. Yuan et al., “Identification of a new fibroblast growth factor receptor, FGFR5,” Gene, vol. 271, no. 2, pp. 171–182, 2001.
- B. Trueb, S. C. Neuhauss, S. Baertschi, T. Rieckmann, C. Schild, and S. Taeschler, “Fish possess multiple copies of fgfrl1, the gene for a novel FGF receptor,” Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, vol. 1727, no. 1, pp. 65–74, 2005.
- M. Wiedemann and B. Trueb, “Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors,” Genomics, vol. 69, no. 2, pp. 275–279, 2000.
- X. Yang, F. Steinberg, L. Zhuang, R. Bessey, and B. Trueb, “Receptor FGFRL1 does not promote cell proliferation but induces cell adhesion,” International Journal of Molecular Medicine, vol. 38, no. 1, pp. 30–38, 2016.
- L. Zhuang, F. Steinberg, and B. Trueb, “Receptor FGFRL1 acts as a tumor suppressor in nude mice when overexpressed in HEK 293 Tet-On cells,” Oncology Letters, vol. 12, no. 6, pp. 4524–4530, 2016.
- A. Kiba, K. Banno, M. Yanokura et al., “Differential mRNA expression profiling in ovarian endometriotic tissue with versus without leuprolide acetate treatment,” The Journal of Obstetrics and Gynaecology Research, vol. 41, no. 10, pp. 1598–1606, 2015.
- L. Zhuang, A. V. Pandey, P. M. Villiger, and B. Trueb, “Cell-cell fusion induced by the Ig3 domain of receptor FGFRL1 in CHO cells,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1853, no. 10, pp. 2273–2285, 2015.
- B. Trueb, R. Amann, and S. D. Gerber, “Role of FGFRL1 and other FGF signaling proteins in early kidney development,” Cellular and Molecular Life Sciences, vol. 70, no. 14, pp. 2505–2518, 2013.
- P. N. Silva, S. M. Altamentova, D. M. Kilkenny, and J. V. Rocheleau, “Fibroblast growth factor receptor like-1 (FGFRL1) interacts with SHP-1 phosphatase at insulin secretory granules and induces beta-cell ERK1/2 protein activation,” Journal of Biological Chemistry, vol. 288, no. 24, pp. 17859–17870, 2013.
- C. L. Barrett, C. DeBoever, K. Jepsen, C. C. Saenz, D. A. Carson, and K. A. Frazer, “Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 23, pp. E3050–E3057, 2015.
- J. Zuo, M. Wen, M. Lei, X. Peng, X. Yang, and Z. Liu, “MiR-210 links hypoxia with cell proliferation regulation in human Laryngocarcinoma cancer,” Journal of Cellular Biochemistry, vol. 116, no. 6, pp. 1039–1049, 2015.
- S. Tsuchiya, “The role of MicroRNA-210 in esophageal squamous cell carcinoma,” Yakugaku Zasshi, vol. 132, no. 9, pp. 1069–1073, 2012.
- S. Tsuchiya, T. Fujiwara, F. Sato et al., “MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1),” Journal of Biological Chemistry, vol. 286, no. 1, pp. 420–428, 2011.
- D. Wu and P. Yotnda, “Induction and testing of hypoxia in cell culture,” Journal of Visualized Experiments, no. 54, 2011.
- E. R. King, C. S. Tung, Y. T. Tsang et al., “The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer,” American Journal of Surgical Pathology, vol. 35, no. 6, pp. 904–912, 2011.
- S. C. Mok, T. Bonome, V. Vathipadiekal et al., “A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2,” Cancer Cell, vol. 16, no. 6, pp. 521–532, 2009.
- K. Yoshihara, A. Tajima, D. Komata et al., “Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis,” Cancer Science, vol. 100, no. 8, pp. 1421–8, 2009.
- R. L. Jensen, “Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target,” Journal of Neuro-Oncology, vol. 92, no. 3, pp. 317–335, 2009.
- K. Selvendiran, A. Bratasz, M. L. Kuppusamy, M. F. Tazi, B. K. Rivera, and P. Kuppusamy, “Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3,” International Journal of Cancer, vol. 125, no. 9, pp. 2198–2204, 2009.
- L. H. Higgins, H. G. Withers, A. Garbens et al., “Hypoxia and the metabolic phenotype of prostate cancer cells,” Biochimica et Biophysica Acta (BBA) - Bioenergetics, vol. 1787, no. 12, pp. 1433–1443, 2009.
- H. Zhong, A. M. De Marzo, E. Laughner et al., “Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases,” Cancer Research, vol. 59, no. 22, pp. 5830–5835, 1999.
- K. L. Talks, H. Turley, K. C. Gatter et al., “The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages,” The American Journal of Pathology, vol. 157, no. 2, pp. 411–421, 2000.
- M. Olbryt, A. Habryka, S. Student, M. Jarzab, T. Tyszkiewicz, and K. M. Lisowska, “Global gene expression profiling in three tumor cell lines subjected to experimental cycling and chronic hypoxia,” PLoS One, vol. 9, no. 8, article e105104, 2014.
Copyright © 2018 Haiyan Tai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.